Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Riluzole for PTSD: Efficacy of a Glutamatergic Modulator as Augmentation Treatment for Posttraumatic Stress Disorder

Next Previous
Search
Trial Profile

Riluzole for PTSD: Efficacy of a Glutamatergic Modulator as Augmentation Treatment for Posttraumatic Stress Disorder

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Riluzole (Primary)
  • Indications Post-traumatic stress disorders
  • Focus Therapeutic Use

Most Recent Events

  • 27 Oct 2020 Results published in the Journal of Clinical Psychiatry
  • 25 Sep 2020 Primary endpoint (Clinician Administered PTSD Scale (CAPS) Score) has not been met as per results published in the ClinicalTrials.gov Trial Registry
  • 25 Sep 2020 Results published in the ClinicalTrials.gov Trial Registry

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top